Rob Davis (Merck)
May 19, 2021 05:38 AM EDTUpdated 11:01 AM
Bioregnum
Pharma

There’s a new team oc­cu­py­ing the ex­ec­u­tive suite at Mer­ck. And they’ve got a new game plan

Now that Rob Davis and his new­ly re­cruit­ed crew of C-suite ex­ecs are about to take full con­trol of Mer­ck, it’s time to up­date the …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Lil­ly beats No­vo in bell­wether head-to-head weight loss study

Lil­ly drops body mass ranges from FDA la­bel for weight loss drug

GSK ter­mi­nates Phase 2 tri­al of HBV ther­a­peu­tic vac­cine

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Co­herus makes fi­nal, $483M piv­ot away from biosim­i­lars

A service from the Financial Times